What is the official website of Takeda Oncology ?

The official website of Takeda Oncology is http://www.takedaoncology.com.

What is Takeda Oncology's cybersecurity risk score?

Takeda Oncology has an AI-generated cybersecurity risk score of 764 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Takeda Oncology experienced?

According to Rankiteo, Takeda Oncology currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Takeda Oncology been affected by any supply chain cyber incidents ?

According to Rankiteo, Takeda Oncology has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Takeda Oncology have SOC 2 Type 1 certification ?

According to Rankiteo, Takeda Oncology is not certified under SOC 2 Type 1.

Does Takeda Oncology have SOC 2 Type 2 certification ?

According to Rankiteo, Takeda Oncology does not hold a SOC 2 Type 2 certification.

Does Takeda Oncology comply with GDPR ?

According to Rankiteo, Takeda Oncology is not listed as GDPR compliant.

Does Takeda Oncology have PCI DSS certification ?

According to Rankiteo, Takeda Oncology does not currently maintain PCI DSS compliance.

Does Takeda Oncology comply with HIPAA ?

According to Rankiteo, Takeda Oncology is not compliant with HIPAA regulations.

Does Takeda Oncology have ISO 27001 certification ?

According to Rankiteo,Takeda Oncology is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Takeda Oncology operate in ?

Takeda Oncology operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Takeda Oncology have ?

Takeda Oncology employs approximately 1,665 people worldwide.

Does Takeda Oncology own any subsidiaries ?

Takeda Oncology presently has no subsidiaries across any sectors.

How many LinkedIn followers does Takeda Oncology have ?

Takeda Oncology's official LinkedIn profile has approximately 159,520 followers.

What is the NAICS classification code for Takeda Oncology ?

Takeda Oncology is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Takeda Oncology have a Crunchbase profile ?

No, Takeda Oncology does not have a profile on Crunchbase.

Does Takeda Oncology have a LinkedIn profile ?

Yes, Takeda Oncology maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/takedaoncology.

How many cybersecurity incidents has Takeda Oncology experienced ?

As of June 24, 2026, Rankiteo reports that Takeda Oncology has experienced 1 cybersecurity incidents.

How many peer or competitor companies does Takeda Oncology have ?

Takeda Oncology has an estimated 5,695 peer or competitor companies worldwide.

What types of cybersecurity incidents has Takeda Oncology faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Takeda Oncology

Boost Score +25 with badge (5 left)

764

/1000

Fair

789

/1000

Fair

Takeda Oncology Vendor Cyber Rating & Cyber Score

takedaoncology.com

Add Your Compliance Badge

Takeda Oncology is the Global Oncology Business Unit of Takeda Pharmaceutical Company Limited. At Takeda, we are united by our aspiration to cure cancer. Drawing on decades of leadership in oncology, we strive to develop innovative treatments that make a difference in the lives of people living with cancer. Our research and development efforts are focused on advancing medicines for thoracic, gastrointestinal and hematologic cancers by leveraging modalities best suited to treat these diseases. Our in-house expertise and innovation are complemented by our valued partners. We fuel these relationships with respect, scientific rigor and a shared commitment to address the most urgent needs of patients. Our diverse global team fosters

Takeda Oncology A.I CyberSecurity Scoring

Scoring History

Takeda Oncology

Takeda Oncology CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Takeda Oncology

Breach

1/2024

BIO201072825

Loading…

A.I.

Takeda Oncology Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Takeda Oncology

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Takeda Oncology in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Takeda Oncology in 2026.

Incident Types Takeda Oncology vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Takeda Oncology in 2026.

Incident History - Takeda Oncology (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Takeda Oncology Subsidiaries

Takeda Oncology

Pharmaceutical Manufacturing

Website: http://www.takedaoncology.com

Company Size: 1,665

TakedaPharmaceutical Manufacturing

BioLife Plasma ServicesPharmaceutical Manufacturing

Takeda Canada Inc.Pharmaceutical Manufacturing

TAKEDA IBDpointServizi benessere e fitness

Dengue AcademyArzneimittelherstellung

ARIAD Pharmaceuticals, Inc.Pharmaceutical Manufacturing

Loading…

Takeda Oncology Similar Companies

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

EMS

cb ems.com.br

Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.

Grifols

cb linktr.ee

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people all over the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries. Patient needs and our ever-growing knowledge of many chronic, rare and prevalent diseases, sometimes life-threatening, drive our innovation in plasma-based therapies and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. With a workforce of over 23,000 employees in more than 30 countries and regions, we are committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership in the industry. Our work has a positive social and economic impact in the countries where we operate, creating jobs and generating wealth. People are at the heart of what we do, and we strive to create an inclusive, diverse, fair and equal society. Maintaining and promoting a workforce that reflects this reality leads to enhanced professional relationships and helps us to give our best to patients, donors and customers. In 2024, Grifols was named one of TIME’s ‘World’s Best Companies’ for the second year in a row, reaffirming our commitment to excellence. We were also recognized by Forbes as one of the "Best Employers for Women 2023," reflecting our dedication to fostering an inclusive and supportive workplace for all. To maintain a positive community and overall respectful communication, please keep our community guidelines in mind.

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Loading…

NEWS

Takeda Oncology CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 28, 2026 08:00 AM

Hexagon Health congratulates Brian Nwokorie, PharmD at Takeda Oncology on being named to MM+M’s 40 Under 40 list

NEW YORK, NY, UNITED STATES, January 28, 2026 /EINPresswire.com/ — Hexagon Health is proud to congratulate Brian Nwokorie, PharmD, Global Brand Lead for...

Read Article

October 22, 2025 07:00 AM

China's Innovent signs cancer therapy deal with Japan's Takeda

Japan's Takeda Pharmaceutical Co has signed a deal with Innovent Biologics to accelerate development of the Chinese drugmaker's oncology...

Read Article

October 21, 2025 07:00 AM

Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors

Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive...

Read Article

September 27, 2024 07:00 AM

Tempus AI expands oncology collaboration with Takeda

The collaboration aims to utilise Tempus' real-world data and biological modelling to enhance the development of Takeda's oncology treatment portfolio.

Read Article

September 24, 2024 07:00 AM

Takeda’s FRUZAQLA gains approval in Japan for colorectal cancer

Takeda has secured the Japanese MHLW approval for its FRUZAQLA to treat unresectable advanced or recurrent colorectal cancer (CRC).

Read Article

October 03, 2023 07:00 AM

Takeda withdraws cancer drug Exkivity after Phase III trial failure

Takeda Pharmaceuticals has started the process for a voluntary withdrawal of Exkivity (mobocertinib) in the US after a confirmatory Phase III trial failed to...

Read Article

January 26, 2023 08:00 AM

Takeda One Ups Pfizer, Moderna with 600,000 SF R&D Office in Cambridge

Takeda Invests in 600000-square-foot facility in Kendall Square, next to Pfizer and Moderna for research and development.

Read Article

January 09, 2017 08:00 AM

Japan's Takeda to buy U.S. cancer drug maker Ariad in $5.2 billion deal

Japan's Takeda Pharmaceutical Co Ltd said it would buy cancer drug maker Ariad Pharmaceuticals Inc in a deal valued at $5.20 billion,...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-56785

SUMMARY

FlatPress versions prior to commit 10be83c, contains a stored cross-site scripting vulnerability in comment and contact forms where name, URL, and email fields are rendered without proper output encoding in Smarty templates. Attackers can inject arbitrary HTML and JavaScript through these fields to execute malicious scripts in browsers of viewers including administrators, or bypass URL scheme validation to inject javascript: or data: URIs.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 8.2)

cvss3

Base Score: 8.2

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:L/A:N

cvss4

Base Score: 8.4

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:H/VI:L/VA:N/SC:H/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

4.7

Exploitability

2.8

REFERENCES

CVE-2026-54588

SUMMARY

Poweradmin is a web-based DNS administration tool for PowerDNS server. Versions prior to 4.2.4 and 4.3.3 use the attacker-controlled `HTTP_HOST` request header as the authoritative source for building callback URLs in its OIDC, SAML, and logout authentication flows without any validation. An unauthenticated attacker can poison the `redirect_uri` sent to the Identity Provider, causing the IdP to redirect the victim's authorization code to an attacker-controlled server - resulting in full account takeover with no credentials required. Versions 4.2.4 and 4.3.3 patch the issue.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 9.6)

cvss3

Base Score: 9.6

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:H/I:H/A:L

Impact Score

Exploitability

2.8

REFERENCES

CVE-2026-48493

SUMMARY

Snipe-IT is an IT asset/license management system. In versions prior to 8.6.0, a user with only users.edit can send a PATCH to /api/v1/users/{their_own_id} and grant themselves any permission except admin and superuser — for example `assets.view`, `assets.create`, `reports.view`, import, etc. The issue is patched in version 8.6.0.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:N/S:U/C:L/I:H/A:N

Impact Score

4.2

Exploitability

1.2

REFERENCES

CVE-2026-47693

SUMMARY

Poweradmin is a web-based DNS administration tool for PowerDNS server. Versions prior to 4.2.4 and 4.3.3 are vulnerable to CSV Injection (Formula Injection) in its log export functionality. User-controlled data — specifically the username field — is written to exported CSV files without sanitizing formula trigger characters (=, +, -, @). When an administrator exports activity logs and opens the resulting CSV in a spreadsheet application (Microsoft Excel, LibreOffice Calc, Google Sheets), any formula stored in a username is executed by the application. This can be used for phishing attacks against administrators or data exfiltration. Versions 4.2.4 and 4.3.3 patch the issue.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 6.9)

cvss3

Base Score: 6.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:R/S:C/C:H/I:L/A:N

Impact Score

4.7

Exploitability

1.7

REFERENCES

CVE-2026-12164

SUMMARY

Fortra File Integrity Monitoring (FIM), formerly Tripwire Enterprise, versions prior to 9.4.0 may assign incorrect or elevated effective permissions to users created by the tetool import command while FIM is running, particularly when the import also creates or changes roles or role-permission relationships.

Published

Date2026-06-23

Updated

Date2026-06-23

RISK INFORMATION (Score: 4.4)

cvss3

Base Score: 4.4

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:H/UI:N/S:U/C:N/I:H/A:N

Impact Score

3.6

Exploitability

0.8

REFERENCES

https://www.fortra.com/security/advisories/product-security/fi-2026-010

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…